Adoptively Transferred in vitro-Generated Myeloid-Derived Suppressor Cells Improve T-Cell Function and Antigen-Specific Immunity after Traumatic Lung Injury.

Cellular immunity Immunotherapy Myeloid-derived suppressor cells Post-traumatic immunosuppression Secondary infection Trauma

Journal

Journal of innate immunity
ISSN: 1662-8128
Titre abrégé: J Innate Immun
Pays: Switzerland
ID NLM: 101469471

Informations de publication

Date de publication:
10 Jun 2022
Historique:
received: 20 12 2021
accepted: 07 05 2022
entrez: 12 6 2022
pubmed: 13 6 2022
medline: 13 6 2022
Statut: aheadofprint

Résumé

Immune reactions after trauma are characterized by immediate activation of innate immunity and simultaneously downregulation of adaptive immunity leading to a misbalanced immunohomeostasis and immunosuppression of the injured host. Therefore, the susceptibility to secondary infections is strongly increased after trauma. Immune responses are regulated by a network of immune cells influencing each other and at the same time modifying their functions dependent on the inflammatory environment. Although myeloid-derived suppressor cells (MDSCs) are initially described as T-cell suppressors, their immunomodulatory capacity after trauma is mostly undefined. Therefore, in vitro-generated MDSCs were adoptively transferred into mice after blunt chest trauma (TxT). A single MDSC treatment-induced splenic T-cell expansion decreased apoptosis sensitivity and improved proliferation in the absence of T-cell exhaustion until 2 weeks after trauma. MDSC treatment had a long-lasting effect on the genomic landscape of CD4+ T cells by upregulating primarily Th2-associated genes. Remarkably, immune-activating functions of MDSCs supported the ability of TxT mice to respond to post-traumatic secondary antigen challenge. Secondary insults were mimicked by immunizing MDSC-treated TxT mice with ovalbumin (OVA), followed by OVA restimulation in vitro. MDSC treatment significantly increased the frequency of OVA-specific T cells, enhanced their Th1/Th2 cytokine expression, and induced upregulation of cytolytic molecules finally improving OVA-specific cytotoxicity. Overall, we could show that therapeutic MDSC treatment after TxT improves post-traumatic T-cell functions, which might enable the traumatic host to counterbalance trauma-induced immunoparalysis.

Identifiants

pubmed: 35691281
pii: 000525088
doi: 10.1159/000525088
pmc: PMC10643914
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-18

Informations de copyright

© 2022 The Author(s). Published by S. Karger AG, Basel.

Références

J Immunol. 2006 Feb 15;176(4):2085-94
pubmed: 16455964
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Neuroscience. 2019 May 15;406:457-466
pubmed: 30880103
Sci Rep. 2019 May 29;9(1):7992
pubmed: 31142770
Bioinformatics. 2002 Jan;18(1):207-8
pubmed: 11836235
Genome Biol. 2003;4(4):R28
pubmed: 12702209
Blood. 2000 Dec 1;96(12):3838-46
pubmed: 11090068
Sci Rep. 2017 Oct 9;7(1):12808
pubmed: 28993671
Stem Cell Res Ther. 2018 Jul 4;9(1):183
pubmed: 29973247
J Exp Med. 1998 Jan 5;187(1):129-34
pubmed: 9419219
Crit Care. 2014 Aug 01;18(4):R163
pubmed: 25084831
Blood. 2010 Dec 16;116(25):5738-47
pubmed: 20807889
J Immunol. 2003 Aug 1;171(3):1172-82
pubmed: 12874203
Oncotarget. 2016 Apr 5;7(14):17565-78
pubmed: 27007050
J Exp Med. 2007 Jun 11;204(6):1463-74
pubmed: 17548519
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
Adv Cancer Res. 2015;128:95-139
pubmed: 26216631
J Trauma Acute Care Surg. 2012 Sep;73(3):699-703
pubmed: 22710768
Crit Care Med. 2005 Jun;33(6):1351-8
pubmed: 15942355
Ann Rheum Dis. 2019 Jul;78(7):957-966
pubmed: 31040119
Biostatistics. 2003 Apr;4(2):249-64
pubmed: 12925520
Fac Rev. 2021 Mar 15;10:30
pubmed: 33817699
Bone. 2016 Dec;93:113-124
pubmed: 27664567
Mediators Inflamm. 2015;2015:458626
pubmed: 25709155
Cancer Immunol Immunother. 2012 Aug;61(8):1319-25
pubmed: 22546994
Autoimmunity. 2017 May;50(3):170-181
pubmed: 28276713
J Leukoc Biol. 2014 Nov;96(5):685-93
pubmed: 24929004
Shock. 2004 Jul;22(1):51-6
pubmed: 15201702
J Clin Immunol. 2013 May;33(4):798-808
pubmed: 23354838
Int J Cancer. 2019 Mar 1;144(5):933-946
pubmed: 29992569
Chin J Traumatol. 2020 Jun;23(3):125-138
pubmed: 32417043
Shock. 2015 Feb;43(2):140-7
pubmed: 25526372
Blood. 2013 Mar 7;121(10):1740-8
pubmed: 23305737
J Biol Chem. 2019 Apr 19;294(16):6283-6293
pubmed: 30787105
J Leukoc Biol. 2021 Dec;110(6):1143-1161
pubmed: 34636072
Blood. 2015 Aug 27;126(9):1138-48
pubmed: 26185131
Hum Immunol. 2016 Aug;77(8):631-636
pubmed: 27240453
Infect Immun. 2012 Jun;80(6):2026-34
pubmed: 22451518
FASEB J. 2019 May;33(5):5967-5978
pubmed: 30730772
J Immunol. 2010 Jun 1;184(11):6151-60
pubmed: 20427766
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
J Trauma. 1996 Jun;40(6):907-12; discussion 912-4
pubmed: 8656476
J Neuroimmunol. 2016 Jan 15;290:96-102
pubmed: 26711577
Shock. 2020 Jan;53(1):35-42
pubmed: 30998650
Br J Cancer. 2019 Jan;120(1):16-25
pubmed: 30413826
Lancet. 2014 Oct 18;384(9952):1455-65
pubmed: 25390327
J Neurochem. 2013 Apr;125(1):74-88
pubmed: 23278273
Front Microbiol. 2016 Oct 13;7:1624
pubmed: 27790210
Mol Med. 2011 Mar-Apr;17(3-4):281-92
pubmed: 21085745
J Clin Invest. 2021 Mar 15;131(6):
pubmed: 33492309
Front Immunol. 2021 Jul 14;12:695972
pubmed: 34341659
J Exp Med. 2010 Jul 5;207(7):1453-64
pubmed: 20530204
JAMA. 2011 Dec 21;306(23):2594-605
pubmed: 22187279
Int Immunopharmacol. 2020 Jun;83:106421
pubmed: 32217462
Am J Respir Crit Care Med. 2017 Aug 1;196(3):315-327
pubmed: 28146645
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Nat Immunol. 2018 Apr;19(4):327-341
pubmed: 29507356
J Immunol. 2018 Mar 1;200(5):1543-1553
pubmed: 29463691
Circulation. 2018 Jul 10;138(2):181-197
pubmed: 29437117
Heart. 2018 May;104(9):719-724
pubmed: 29203574
JAMA. 2011 Mar 9;305(10):1001-7
pubmed: 21386078
PLoS One. 2016 Oct 25;11(10):e0164514
pubmed: 27780254

Auteurs

Monika Kustermann (M)

Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.

Prasad Dasari (P)

Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.

Ingrid Knape (I)

Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.

Emma Keltsch (E)

Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.

Jianing Liu (J)

Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.

Silvia Pflüger (S)

Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.

Wolfram Osen (W)

GMP & T Cell Therapy, German Cancer Research Center, Heidelberg, Germany.

Karlheinz Holzmann (K)

Genomic-Core Facility, University Ulm, Ulm, Germany.

Markus Huber-Lang (M)

Institute of Experimental Trauma-Immunology, University Medical Center Ulm, Ulm, Germany.

Klaus-Michael Debatin (KM)

Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.

Gudrun Strauss (G)

Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.

Classifications MeSH